日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study

Ucenprubart 是一种 CD200R 激动性抗体,具有治疗炎症性皮肤病的潜力:临床前开发和 I 期临床研究

Anja Koester ,Derrick R Witcher ,Mark Lee ,Stephen J Demarest ,Scott Potter ,Katie Werle ,Scott Bauer ,Diana Ruiz ,Laurent Malherbe ,Josh Poorbaugh ,Andrew Glasebrook ,Christoph Preuss ,Gourab Datta ,Ziqiao Wang ,Jack Knorr ,David Manner ,Dipak Patel ,Carsten Schmitz ,Paul Klekotka ,Ajay Nirula

The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination

抗SARS-CoV-2单克隆抗体bamlanivimab对COVID-19疫苗的内源性免疫反应影响甚微。

Robert J Benschop ,Jay L Tuttle ,Lin Zhang ,Josh Poorbaugh ,Nicole L Kallewaard ,Peter Vaillancourt ,Melissa Crisp ,Thi Ngoc Vy Trinh ,Joshua J Freitas ,Stephanie Beasley ,Montanea Daniels ,Natalie Haustrup ,Richard E Higgs ,Ajay Nirula ,Myron S Cohen ,Mary Marovich

Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab

接受中和单克隆抗体 bamlanivimab 治疗后,住院 COVID-19 患者鼻咽拭子基因表达模式与血清生物标志物之间的关系

Jonathan T Sims, Josh Poorbaugh, Ching-Yun Chang, Timothy R Holzer, Lin Zhang, Sarah M Engle, Stephanie Beasley, Thompson N Doman, Lynn Naughton, Richard E Higgs, Nicole Kallewaard, Robert J Benschop

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together

接受巴姆拉尼维单抗单药治疗或巴姆拉尼维单抗联合依替塞维单抗治疗的轻度或中度 COVID-19 患者体内针对 SARS-CoV-2 的内源性抗体反应

Lin Zhang ,Josh Poorbaugh ,Michael Dougan ,Peter Chen ,Robert L Gottlieb ,Gregory Huhn ,Stephanie Beasley ,Montanea Daniels ,Thi Ngoc Vy Trinh ,Melissa Crisp ,Joshua Joaquin Freitas ,Peter Vaillancourt ,Dipak R Patel ,Ajay Nirula ,Nicole L Kallewaard ,Richard E Higgs ,Robert J Benschop